Pharmacogenetics in the treatment of breast cancer

V. Stearns, N. E. Davidson, D. A. Flockhart

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Preliminary pharmacogenetic data strongly suggest an important role for the use of germline genetic information in the individualization of treatment and prevention of breast cancer. The potential value of these data as individual genotypic predictors may be valuable or, more likely, patterns of genetic markers analogous to the expression profiles obtained from tumor tissue may allow more powerful prediction of who will respond best to a specific treatment or regimen. For the potential of genomic research to be fulfilled, prospective trials with clinical outcomes as end points will have to include the collection of germline DNA either in blood, or by buccal swab. Although the collection of DNA for such pharmacogenetic testing raises a number of important ethical issues that mandate the use of an appropriate informed consent process, sufficient experience has now been catalogued to allow broad guidelines for such an informed consent to be constructed. Investigators are now equipped with robust genetic tools with which to examine in detail multiple relationships between germline genetic variants and response to the treatment of breast cancer. A future in which genetics will contribute to the precise prescription of treatments for breast cancer, with the attendant benefits to patients, is now foreseeable, but much research remains to be done. Critical to this work will be the prospective collection of germline DNA from patients enrolled in large clinical trials of defined treatment with clinical determination of outcome.

Original languageEnglish
Pages (from-to)143-153
Number of pages11
JournalPharmacogenomics Journal
Volume4
Issue number3
DOIs
StatePublished - 2004

Fingerprint

Pharmacogenetics
Breast Neoplasms
Informed Consent
DNA
Clinical Trials
Therapeutics
Cheek
Genetic Markers
Research
Ethics
Prescriptions
Research Personnel
Guidelines
Neoplasms

ASJC Scopus subject areas

  • Pharmacology
  • Molecular Medicine
  • Genetics

Cite this

Stearns, V., Davidson, N. E., & Flockhart, D. A. (2004). Pharmacogenetics in the treatment of breast cancer. Pharmacogenomics Journal, 4(3), 143-153. https://doi.org/10.1038/sj.tpj.6500242

Pharmacogenetics in the treatment of breast cancer. / Stearns, V.; Davidson, N. E.; Flockhart, D. A.

In: Pharmacogenomics Journal, Vol. 4, No. 3, 2004, p. 143-153.

Research output: Contribution to journalArticle

Stearns, V, Davidson, NE & Flockhart, DA 2004, 'Pharmacogenetics in the treatment of breast cancer', Pharmacogenomics Journal, vol. 4, no. 3, pp. 143-153. https://doi.org/10.1038/sj.tpj.6500242
Stearns, V. ; Davidson, N. E. ; Flockhart, D. A. / Pharmacogenetics in the treatment of breast cancer. In: Pharmacogenomics Journal. 2004 ; Vol. 4, No. 3. pp. 143-153.
@article{40d6f392e4bf49babf1ea9ee32151c18,
title = "Pharmacogenetics in the treatment of breast cancer",
abstract = "Preliminary pharmacogenetic data strongly suggest an important role for the use of germline genetic information in the individualization of treatment and prevention of breast cancer. The potential value of these data as individual genotypic predictors may be valuable or, more likely, patterns of genetic markers analogous to the expression profiles obtained from tumor tissue may allow more powerful prediction of who will respond best to a specific treatment or regimen. For the potential of genomic research to be fulfilled, prospective trials with clinical outcomes as end points will have to include the collection of germline DNA either in blood, or by buccal swab. Although the collection of DNA for such pharmacogenetic testing raises a number of important ethical issues that mandate the use of an appropriate informed consent process, sufficient experience has now been catalogued to allow broad guidelines for such an informed consent to be constructed. Investigators are now equipped with robust genetic tools with which to examine in detail multiple relationships between germline genetic variants and response to the treatment of breast cancer. A future in which genetics will contribute to the precise prescription of treatments for breast cancer, with the attendant benefits to patients, is now foreseeable, but much research remains to be done. Critical to this work will be the prospective collection of germline DNA from patients enrolled in large clinical trials of defined treatment with clinical determination of outcome.",
author = "V. Stearns and Davidson, {N. E.} and Flockhart, {D. A.}",
year = "2004",
doi = "10.1038/sj.tpj.6500242",
language = "English",
volume = "4",
pages = "143--153",
journal = "Pharmacogenomics Journal",
issn = "1470-269X",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Pharmacogenetics in the treatment of breast cancer

AU - Stearns, V.

AU - Davidson, N. E.

AU - Flockhart, D. A.

PY - 2004

Y1 - 2004

N2 - Preliminary pharmacogenetic data strongly suggest an important role for the use of germline genetic information in the individualization of treatment and prevention of breast cancer. The potential value of these data as individual genotypic predictors may be valuable or, more likely, patterns of genetic markers analogous to the expression profiles obtained from tumor tissue may allow more powerful prediction of who will respond best to a specific treatment or regimen. For the potential of genomic research to be fulfilled, prospective trials with clinical outcomes as end points will have to include the collection of germline DNA either in blood, or by buccal swab. Although the collection of DNA for such pharmacogenetic testing raises a number of important ethical issues that mandate the use of an appropriate informed consent process, sufficient experience has now been catalogued to allow broad guidelines for such an informed consent to be constructed. Investigators are now equipped with robust genetic tools with which to examine in detail multiple relationships between germline genetic variants and response to the treatment of breast cancer. A future in which genetics will contribute to the precise prescription of treatments for breast cancer, with the attendant benefits to patients, is now foreseeable, but much research remains to be done. Critical to this work will be the prospective collection of germline DNA from patients enrolled in large clinical trials of defined treatment with clinical determination of outcome.

AB - Preliminary pharmacogenetic data strongly suggest an important role for the use of germline genetic information in the individualization of treatment and prevention of breast cancer. The potential value of these data as individual genotypic predictors may be valuable or, more likely, patterns of genetic markers analogous to the expression profiles obtained from tumor tissue may allow more powerful prediction of who will respond best to a specific treatment or regimen. For the potential of genomic research to be fulfilled, prospective trials with clinical outcomes as end points will have to include the collection of germline DNA either in blood, or by buccal swab. Although the collection of DNA for such pharmacogenetic testing raises a number of important ethical issues that mandate the use of an appropriate informed consent process, sufficient experience has now been catalogued to allow broad guidelines for such an informed consent to be constructed. Investigators are now equipped with robust genetic tools with which to examine in detail multiple relationships between germline genetic variants and response to the treatment of breast cancer. A future in which genetics will contribute to the precise prescription of treatments for breast cancer, with the attendant benefits to patients, is now foreseeable, but much research remains to be done. Critical to this work will be the prospective collection of germline DNA from patients enrolled in large clinical trials of defined treatment with clinical determination of outcome.

UR - http://www.scopus.com/inward/record.url?scp=2942735013&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2942735013&partnerID=8YFLogxK

U2 - 10.1038/sj.tpj.6500242

DO - 10.1038/sj.tpj.6500242

M3 - Article

C2 - 15024382

AN - SCOPUS:2942735013

VL - 4

SP - 143

EP - 153

JO - Pharmacogenomics Journal

JF - Pharmacogenomics Journal

SN - 1470-269X

IS - 3

ER -